BidaskClub lowered shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a hold rating to a sell rating in a research report report published on Thursday morning.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald set a $7.00 target price on Endo International and gave the stock a hold rating in a research note on Thursday. Mizuho reiterated a buy rating and set a $12.00 target price (down from $14.00) on shares of Endo International in a research note on Wednesday, January 3rd. Leerink Swann initiated coverage on Endo International in a research note on Tuesday, January 2nd. They issued an outperform rating and a $12.00 price objective on the stock. ValuEngine cut Endo International from a buy rating to a hold rating in a research note on Sunday, December 31st. Finally, Vetr upgraded Endo International from a buy rating to a strong-buy rating and set a $8.92 price objective on the stock in a research note on Tuesday, December 26th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $11.27.

Endo International (ENDP) traded up $0.03 during midday trading on Thursday, hitting $7.95. The stock had a trading volume of 4,319,100 shares, compared to its average volume of 7,334,944. The company has a market cap of $1,780.00, a PE ratio of -0.41, a price-to-earnings-growth ratio of 2.73 and a beta of 0.59. Endo International has a 12 month low of $5.77 and a 12 month high of $14.45. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The business’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.01 EPS. equities research analysts forecast that Endo International will post 3.67 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Riverhead Capital Management LLC increased its position in shares of Endo International by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares during the period. Van ECK Associates Corp increased its position in shares of Endo International by 3.1% during the second quarter. Van ECK Associates Corp now owns 204,118 shares of the company’s stock valued at $2,280,000 after buying an additional 6,158 shares during the period. Flinton Capital Management LLC increased its position in shares of Endo International by 64.4% during the second quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock valued at $228,000 after buying an additional 7,990 shares during the period. Hunter Associates Investment Management LLC increased its position in shares of Endo International by 26.8% during the second quarter. Hunter Associates Investment Management LLC now owns 43,000 shares of the company’s stock valued at $480,000 after buying an additional 9,100 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in shares of Endo International by 1.6% during the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after buying an additional 10,387 shares during the period. Hedge funds and other institutional investors own 93.06% of the company’s stock.

WARNING: “BidaskClub Lowers Endo International (ENDP) to Sell” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/01/15/bidaskclub-lowers-endo-international-endp-to-sell.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.